Difference between revisions of "TRK fusions"
Jump to navigation
Jump to search
| Line 12: | Line 12: | ||
==Association== | ==Association== | ||
*[[Mammary analogue secretory carcinoma]] (MASC) - ''ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal | last1 = Lei | first1 = Y. | last2 = Chiosea | first2 = SI. | title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. | journal = Head Neck Pathol | volume = 6 | issue = 2 | pages = 166-70 | month = Jun | year = 2012 | doi = 10.1007/s12105-011-0312-9 | PMID = 22127547 }}</ref> | *[[Mammary analogue secretory carcinoma]] (MASC) - ''ETV6-NTRK3.<ref name=pmid22127547>{{Cite journal | last1 = Lei | first1 = Y. | last2 = Chiosea | first2 = SI. | title = Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. | journal = Head Neck Pathol | volume = 6 | issue = 2 | pages = 166-70 | month = Jun | year = 2012 | doi = 10.1007/s12105-011-0312-9 | PMID = 22127547 }}</ref> | ||
*Secretory breast carcinoma - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal | last1 = Vasudev | first1 = P. | last2 = Onuma | first2 = K. | title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. | journal = Arch Pathol Lab Med | volume = 135 | issue = 12 | pages = 1606-10 | month = Dec | year = 2011 | doi = 10.5858/arpa.2010-0351-RS | PMID = 22129193 }}</ref> | *[[Secretory breast carcinoma]] - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal | last1 = Vasudev | first1 = P. | last2 = Onuma | first2 = K. | title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. | journal = Arch Pathol Lab Med | volume = 135 | issue = 12 | pages = 1606-10 | month = Dec | year = 2011 | doi = 10.5858/arpa.2010-0351-RS | PMID = 22129193 }}</ref> | ||
==Drugs== | ==Drugs== | ||
Revision as of 05:44, 11 September 2018
TRK fusions are seen in many solid tumours and have targeted drugs.
Genes:
- TRK1
- TRK2
- TRK3
The TRK genes are tyrosine kinase receptors.
Multiple fusion partners for each gene.
Association
- Mammary analogue secretory carcinoma (MASC) - ETV6-NTRK3.[1]
- Secretory breast carcinoma - ETV6-NTRK3.[2]
Drugs
- Merestinib.
- Larotrectinib.
- Others.
See also
References
- ↑ Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.